This complex has been shown to be cytotoxic to human HeLa cells in only seven days compared to the control, which kept growing past seven days. peptides alone or in combination with carrier molecules including nanoparticles and viruses. == Major conclusions == Targeting the TfR has been shown Phellodendrine chloride to be effective in delivering many different therapeutic agents and causing cytotoxic effects in malignancy cellsin vitroandin vivo. == General significance == The considerable use of TfR for targeted therapy attests to the versatility of targeting this receptor for therapeutic purposes against malignant cells. More advances in this area are expected to further improve the therapeutic potential of targeting the TfR for malignancy therapy leading to an increase in the number of clinical trials of molecules targeting this receptor. Keywords:transferrin receptor, CD71, malignancy, nanoparticles, immunotoxins, delivery, conjugates, gene therapy == 1. Introduction == The receptor for transferrin Rabbit Polyclonal to SF3B4 (Tf), referred Phellodendrine chloride to as TfR1 (also known as CD71), is usually ubiquitously expressed at low levels in most normal human tissues. A second member of the TfR family is usually TfR2, a protein that is highly homologous to TfR1 but whose expression is largely restricted to hepatocytes [1]. Serving as the main port of access for iron bound Tf into cells, TfR1 is usually a type-II receptor that resides around the Phellodendrine chloride outer cell membrane and cycles into acidic endosomes into the cell in a clathrin/dynamin dependent manner [1-4]. Iron is usually delivered into the cell and TfR1 is usually recycled back to the cell surface (Physique 1-2) [5,6]. Despite its ubiquitous expression, TfR1 is usually expressed on malignant cells at levels many times higher than those on normal cells and its expression can be correlated with tumor stage or malignancy progression [7-12]. This high expression of the receptor on malignant cells, its ability to internalize, and the necessity of iron for malignancy cell proliferation make this receptor a widely accessible portal for the delivery of drugs into malignant cells and thus, an attractive target for malignancy therapy (Physique 3). == Physique 1. Schematic representation of the TfR1 and cellular uptake of iron through the Tf system via receptor-mediated endocytosis. == (A) TfR1 is found around the cell surface as a homodimer consisting of two monomers linked by disulfide bridges at cysteines 89 and 98 (). The TfR Phellodendrine chloride contains an intracellular domain name, a transmembrane domain name, and a large extracellular domain name. There is an O-linked glycosylation site at threonine 104 () and three N-linked glycosylation sites on arginine residues 251, 317 and 727 (). The extracellular domain name of the TfR consists of three subdomains: apical (A), helical (H) and protease-like domain name (P). (B) Each receptor monomer binds one Tf molecule that consists of two lobes (the N and C lobes). Each lobe of Tf binds one iron molecule and thus two diferric Tf molecules bind to the receptor with high affinity. (C) Endocytosis of the diferric Tf/TfR complex occurs via clathrin-coated pits and the complex is usually delivered into endosomes. Protons are pumped into the endosome resulting in a decrease in pH that stimulates a conformational switch in Tf and its subsequent release of iron. The iron is usually then transported out of the endosome into the cytosol by the DMT1. Apotransferrin remains bound to the TfR while in the endosome and is only released once the complex reaches the cell surface. Figure is usually reprinted from [1] with permission from Elsevier. == Phellodendrine chloride Physique 2. Internalization of Tf by TfR1. == Side and top views of the TfR alone (1) or bound to Tf (2). Figures in the physique correspond to the figures and explanations outlined on the right side of the physique. == Physique 3. Strategies for targeting therapeutic brokers via TfR to malignant cells. == Targeting can be mediated by its natural ligand Tf, a specific peptide,.